6,7-二氢-5H-茚并[5,6-d][1,3]噻唑-2-胺 | 83777-91-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 6,7-二氢-5H-茚并[5,6-d][1,3]噻唑-2-胺
• 英文名称: 6,7-dihydro-5H-indeno[5,6-d]thiazol-2-amine
• 英文别名: SKA-29；6,7-dihydro-5H-cyclopenta[f][1,3]benzothiazol-2-amine
• CAS: 83777-91-7
• 化学式: C₁₀H₁₀N₂S
• 分子量: 190.269
• InChiKey: MPVRQOFISAAHEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6,7-二氢-5H-茚并[5,6-d][1,3]噻唑-2-胺 在 氢氧化钾 、 三乙胺 作用下， 以 乙二醇甲醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 6,7-cyclopenteno-2-<3-<4-(4-fluorophenyl)-1-piperazinyl>propyl>-2H-1,4-benzothiazin-3(4H)-one
  参考文献：
  名称：

  新的1,4-苯并噻嗪衍生物的合成和生物活性。

  摘要：

  合成了新的2H-1,4-苯并噻嗪-3（4H）-在2位具有（4-苯基-1-哌嗪基）烷基部分的衍生物，并测试了其钙拮抗和钙调蛋白拮抗活性。还评估了自发性高血压大鼠的抗高血压作用。通常，这些化合物是相当弱的钙通道阻滞剂，尽管相反，它们中的许多具有中度至强效的钙调蛋白拮抗活性，以及​​2- [3-（4-（4-氟苯基）-1-哌嗪基]丙基]- 2H-1,4-苯并噻嗪-3（4H）-一衍生物45、74和75显示有效的降压作用。

  DOI：

  10.1248/cpb.39.2888
• 作为产物：
  描述：

  1-benzoyl-3-2,3-dihydro-1H-inden-5-ylthiourea 在 溴 、 sodium hydroxide 作用下， 以 溶剂黄146 为溶剂， 反应 3.0h， 生成 6,7-二氢-5H-茚并[5,6-d][1,3]噻唑-2-胺
  参考文献：
  名称：

  De novo tyrosinase inhibitor: 4-(6,7-Dihydro-5H-indeno[5,6-d]thiazol-2-yl)benzene-1,3-diol (MHY1556)

  摘要：

  In this study, we have synthesized and studied de novo tyrosinase inhibitor, MHY1556, which showed significantly better efficacy than other pre-existing tyrosinase inhibitors in vitro experiments. The IC50 value of MHY1556 was 0.50 mu M which was significantly lower than that of kojic acid ( IC50 = 53.95 mu M), which is a well-known tyrosinase inhibitor and was used as a positive control in this study. We predicted the tertiary structure of tyrosinase, simulated the docking with compound MHY1556 and confirmed that the compound strongly interacts with mushroom tyrosinase residues. Substitutions with a hydroxy group at both R1 and R3 of the phenyl ring indicated that these groups play a major role in the high binding affinity to tyrosinase, especially through the hydrogen bonding interaction of the hydroxyl group at R1 with GLY281. In addition, MHY1556 showed concentration-dependent inhibitory effects in melanin content assay where B16F10 melanoma cells were treated with alpha-melanocyte stimulating hormone (alpha-MSH), and also there is no significant cytotoxicity of this compound in cell viability assay conducted in B16F10 melanoma cells. The tyrosinase activity assay results with MHY1556 also support its potent inhibitory effects. Therefore, our data strongly suggest MHY1556 suppresses the melanogenesis via a tyrosinase inhibitory effect. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.029

文献信息

• 신규한 디플루오로아세트산 유도체 화합물 및 이를 포함한 조성물
  申请人：Pusan National University Industry-University Cooperation Foundation 부산대학교 산학협력단(220040044843) BRN ▼621-82-06530

  公开号：KR20200011270A

  公开（公告）日：2020-02-03

  본 발명은 신규한 디플루오로아세트산 유도체 화합물 및 이를 포함하는 다양한 용도의 조성물에 관한 것으로, 상기 디플루오로아세트산 유도체 화합물은 PPARα, β 또는 γ 중 어느 하나를 활성화시키는 어고니스트로서 작용할 수 있을 뿐만 아니라, 이중 효능 또는 삼중 효능을 나타낼 수 있는 바, 따라서 PPARs이 관여하는 대사성 질환을 보다 효과적으로 예방, 개선 내지 치료할 수 있고, 더 나아가 미백 및 주름 개선 활성, 항염증 및 항산화 효과까지 나타낼 수 있으므로, 다양한 조성물로서 유용하게 활용될 수 있다.

  本发明涉及一种新型的二氟乙酸衍生物化合物及包含它的各种用途的组合物，所述二氟乙酸衍生物化合物可以作为激活PPARα、β或γ中任一种的激动剂，不仅可以发挥单一作用，还可以表现出双重或三重效应，因此可以更有效地预防、改善或治疗与PPARs相关的代谢性疾病，同时还表现出美白和减少皱纹的活性，具有抗炎和抗氧化效果，因此可以作为各种组合物中有用的成分。
• NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH
  申请人：The Regents of the University of Michigan

  公开号：US20190183865A1

  公开（公告）日：2019-06-20

  Provided herein are small molecule inhibitors of NSD1, NSD2 and/or NSD3 activity, and methods of use thereof for the treatment of disease, including leukemia, breast cancer, osteosarcoma, lung and prostate cancers and other solid tumors as well as other diseases dependent on the activity of NSD1, NSD2 and/or NSD3.

  本文提供了NSD1、NSD2和/或NSD3活性的小分子抑制剂，以及利用这些抑制剂治疗疾病的方法，包括白血病、乳腺癌、骨肉瘤、肺癌、前列腺癌和其他实体肿瘤，以及其他依赖于NSD1、NSD2和/或NSD3活性的疾病。
• NSD family inhibitors and methods of treatment therewith
  申请人：The Regents of the University of Michigan

  公开号：US11324729B2

  公开（公告）日：2022-05-10

  Provided herein are small molecule inhibitors of NSD1, NSD2 and/or NSD3 activity, and methods of use thereof for the treatment of disease, including leukemia, breast cancer, osteosarcoma, lung and prostate cancers and other solid tumors as well as other diseases dependent on the activity of NSD1, NSD2 and/or NSD3.

  本文提供了NSD1、NSD2和/或NSD3活性的小分子抑制剂及其用于治疗疾病的方法，包括白血病、乳腺癌、骨肉瘤、肺癌和前列腺癌、其他实体瘤以及依赖于NSD1、NSD2和/或NSD3活性的其他疾病。
• Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
  申请人：Iovance Biotherapeutics, Inc.

  公开号：US11357841B2

  公开（公告）日：2022-06-14

  Methods of expanding tumor infiltrating lymphocytes (TILs) using a potassium channel agonist, such as a KCa3.1 (IK channel) agonist, and uses of such expanded TILs in the treatment of diseases such as cancer are disclosed herein.

  本文公开了使用钾通道激动剂（如 KCa3.1（IK 通道）激动剂）扩增肿瘤浸润淋巴细胞（TILs）的方法，以及这种扩增的 TILs 在治疗癌症等疾病中的用途。
• Visible-light-initiated malic acid-promoted cascade coupling/cyclization of aromatic amines and KSCN to 2-aminobenzothiazoles without photocatalyst
  作者：Wei-Bao He、Lan-Qing Gao、Xin-Jie Chen、Zhi-Lin Wu、Ying Huang、Zhong Cao、Xin-Hua Xu、Wei-Min He

  DOI：10.1016/j.cclet.2020.02.011

  日期：2020.7

  By using ambient air as the oxidant and malic acid as the promoter, a practical method for the preparation of 2-aminobenzothiazoles through visible-light-initiated cascade reaction of aromatic amines and KSCN in eco-friendly bis(methoxypropy)ether under metal-, hazardous additive-, photocatalyst-free conditions was established. (C) 2020 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.